Roth Mkm Cuts Tilray (NASDAQ:TLRY) Price Target to $1.75

Tilray (NASDAQ:TLRY) had its price target lowered by investment analysts at Roth Mkm from $2.00 to $1.75 in a note issued to investors on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Roth Mkm’s price objective indicates a potential upside of 12.20% from the company’s previous close.

Tilray Price Performance

Shares of NASDAQ:TLRY opened at $1.56 on Friday. Tilray has a one year low of $1.45 and a one year high of $2.97. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -4.79 and a beta of 2.13. The company has a 50-day simple moving average of $1.76 and a 200-day simple moving average of $1.86. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.42 and a current ratio of 2.27.

Tilray (NASDAQ:TLRY) last announced its earnings results on Thursday, October 10th. The company reported ($0.04) earnings per share for the quarter, meeting the consensus estimate of ($0.04). Tilray had a negative return on equity of 2.63% and a negative net margin of 30.26%. The company had revenue of $200.00 million for the quarter, compared to the consensus estimate of $218.70 million. During the same period last year, the business posted ($0.10) EPS. The company’s revenue was up 13.0% on a year-over-year basis. On average, analysts predict that Tilray will post -0.16 EPS for the current year.

Institutional Investors Weigh In On Tilray

A number of institutional investors have recently added to or reduced their stakes in TLRY. Prospect Financial Services LLC acquired a new position in shares of Tilray during the 2nd quarter worth $26,000. Wellington Wealth Strategies LLC. acquired a new position in Tilray during the fourth quarter worth about $29,000. Signature Estate & Investment Advisors LLC purchased a new position in Tilray in the second quarter valued at about $29,000. Jeppson Wealth Management LLC acquired a new stake in shares of Tilray during the 2nd quarter valued at approximately $33,000. Finally, Vanguard Capital Wealth Advisors acquired a new stake in shares of Tilray during the 2nd quarter valued at approximately $34,000. Hedge funds and other institutional investors own 9.35% of the company’s stock.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.